Yesterday, March 14, 2016, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.92 to $72,390,000.00.

Highlighted Stocks Traded by Insiders:

Asta Funding (ASFI) - FREE Research Report

Leibowitz Harvey, who is Director at Asta Funding, sold 2,000 shares at $8.07 on March 14, 2016. Following this transaction, the Director owned 7,000 shares meaning that the stake was reduced by 22.22% with the 2,000-share transaction.

The shares most recently traded at $9.00, up $0.93, or 10.38% since the insider transaction. Historical insider transactions for Asta Funding go as follows:

  • 4-Week # shares bought: 327,600
  • 12-Week # shares bought: 673,840
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 718,190
  • 24-Week # shares sold: 7,000

The average volume for Asta Funding has been 24,700 shares per day over the past 30 days. Asta Funding has a market cap of $100.0 million and is part of the financial sector and financial services industry. Shares are up 6.16% year-to-date as of the close of trading on Monday.

Asta Funding, Inc., together with its subsidiaries, engages in consumer receivable business in the United States. The company operates through four segments: Consumer Receivables, Personal Injury Claims, Structured Settlements, and GAR Disability Advocacy. The company has a P/E ratio of 30.6. Currently, there are no analysts who rate Asta Funding a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASFI - FREE

TheStreet Quant Ratings

rates Asta Funding as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and poor profit margins. Get the full

Asta Funding Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aceto (ACET) - FREE Research Report

Bartone Raymond, who is Senior Vice President at Aceto, sold 3,000 shares at $22.40 on March 14, 2016. Following this transaction, the Senior Vice President owned 32,109 shares meaning that the stake was reduced by 8.54% with the 3,000-share transaction.

The shares most recently traded at $21.60, down $0.80, or 3.69% since the insider transaction. Historical insider transactions for Aceto go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 15,350
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 15,350
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 31,900

The average volume for Aceto has been 238,300 shares per day over the past 30 days. Aceto has a market cap of $682.9 million and is part of the health care sector and drugs industry. Shares are down 17.24% year-to-date as of the close of trading on Monday.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 17.1. Currently, there is 1 analyst who rates Aceto a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACET - FREE

TheStreet Quant Ratings

rates Aceto as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Aceto Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hydrogenics (HYGS) - FREE Research Report

CommScope, Inc. of North Carolina, who is 10% Owner at Hydrogenics, sold 300 shares at $8.07 on March 14, 2016. Following this transaction, the 10% Owner owned 1.3 million shares meaning that the stake was reduced by 0.02% with the 300-share transaction.

The shares most recently traded at $7.57, down $0.50, or 6.61% since the insider transaction. Historical insider transactions for Hydrogenics go as follows:

  • 4-Week # shares sold: 16,149
  • 12-Week # shares sold: 16,149
  • 24-Week # shares sold: 16,149

The average volume for Hydrogenics has been 73,300 shares per day over the past 30 days. Hydrogenics has a market cap of $96.1 million and is part of the industrial goods sector and industrial industry. Shares are down 13.46% year-to-date as of the close of trading on Monday.

Hydrogenics Corporation, together with its subsidiaries, designs, develops, and manufactures hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. Currently, there are 3 analysts who rate Hydrogenics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HYGS - FREE

TheStreet Quant Ratings

rates Hydrogenics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Hydrogenics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.